BioCryst Pharmaceuticals: RBC Capital keeps Outperform rating, lowers PT to $13

viernes, 30 de enero de 2026, 10:52 am ET1 min de lectura
BCRX--

BioCryst Pharmaceuticals: RBC Capital keeps Outperform rating, lowers PT to $13

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios